Jongdoonghun Jeong, Reporter at the Ministry of Bio-industrial Venture

Jongdoonghun Jeong, Reporter at the Ministry of Bio-industrial Venture

View original image

"If a strike occurs, the losses the company would have to bear are enormous, so please pay the employees in advance as you would pay fire insurance premiums."


This is the logic put forward by the Samsung Biologics labor union during this year’s wage negotiations with management. While the right of workers to collective action must be fully protected, if the method of exercising that right threatens the company itself—the very workplace to which employees belong—such a tactic may become a self-destructive contradiction, regardless of the logic or justification for negotiations. The union has announced it will begin collective action on the 21st of this month, with a strike planned for the 1st of next month.


Looking at the growth history of Samsung Biologics, it becomes clear how self-defeating the union’s negotiation strategy is. Since its founding in 2011, the company has achieved outstanding results, recording KRW 4.5 trillion in sales and KRW 2 trillion in operating profit last year—just 14 years after its establishment—setting a remarkable growth record even within the Samsung Group. This was possible because, from the early and challenging days of the domestic bio industry, the company built trust with clients through meticulous quality control and strict adherence to delivery deadlines.


The very foundation of this competitiveness is what the union is using as a bargaining chip. Continuity is the essence of bio manufacturing processes. The production of biopharmaceuticals, which involves handling living cells, requires continuous operation 24 hours a day, 365 days a year. Unlike general manufacturing, where an assembly line can be stopped and restarted, if a bio process is interrupted, all pharmaceuticals under cultivation must be discarded. This directly undermines order fulfillment competitiveness. The contract development and manufacturing organization (CDMO) business relies entirely on client trust and meeting deadlines. If a strike disrupts production, global clients are highly likely to shift orders to competitors in order to diversify their risks.


Precedents in the overseas pharmaceutical industry clearly demonstrate the consequences of halting operations. In 2017, the union of Israeli pharmaceutical company Teva occupied the plant and launched a full-scale strike in protest against management’s plan to close the Jerusalem factory and implement large-scale restructuring. At the time, the strike was both a struggle to save jobs and a show of force by halting the pharmaceutical supply chain. Nevertheless, it failed to prevent the closure of an uncompetitive plant, resulting in hundreds losing their jobs. Similarly, in 2010, the union at France’s Sanofi Pasteur protested a sub-2% wage increase by occupying the logistics warehouse and halting shipments of the then-popular swine flu vaccine. Some countries had to accept significant threats to their healthcare systems due to supply disruptions. Sanofi suffered severe consequences from its failure to deliver pharmaceuticals promptly during a pandemic. For a CDMO company, whose survival depends on client trust, stopping operations can be even more fatal.



Collective action by the union must be respected only when it is based on an attitude of respect for the community and the workplace. No one can be persuaded by a method that shakes the very foundation of business and threatens the workplace itself. The growth story that Samsung Biologics has built over the past 15 years must not be destroyed by extreme confrontation. It is hoped that both labor and management will actively engage in dialogue to maintain the company’s hard-earned competitiveness.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing